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Abstract: Optogenetic and photopharmacological tools to
manipulate neuronal inhibition have limited efficacy and
reversibility. We report the design, synthesis, and biologi-
cal evaluation of Fulgazepam, a fulgimide derivative of
benzodiazepine that behaves as a pure potentiator of ion-
otropic g-aminobutyric acid receptors (GABAARs) and dis-
plays full and reversible photoswitching in vitro and in
vivo. The compound enables high-resolution studies of
GABAergic neurotransmission, and phototherapies based
on localized, acute, and reversible neuroinhibition.
In the quest to understand brain circuits, controlling neuronal
activity with light has become an essential tool to manipulate
the balance between excitation and inhibition.[1] However, op-
togenetic tools to inhibit neurons (halorhodopsin pumps,
anion-conducting bacterial channelrhodopsins and chloride-
conducting ChR2 mutants)[2–4] have very limited conductance
and dynamic responses to depolarization. Caged g-aminobuty-
ric acid(GABA) compounds have been used to inhibit spines
and to control seizures, but uncaging is irreversible and their
neurotoxicity[5] has been avoided only recently by means of al-
losteric ligands.[6] A powerful alternative is using reversible
chemical photoswitches[7–10] to harness endogenous anion-con-
ducting receptor-channels like GABA and glycine receptors
(GABAAR, GlyR), which mediate inhibitory neurotransmission in
the mammalian central nervous system.[11] Although some
GABAAR photoswitches have been reported based on azoben-
zene,[12–14] this photochromic group displays several shortcom-
ings: it provides incomplete photoconversion due to a sub-
stantial overlap of the absorption maxima of cis and trans iso-
mers, and can alter the pharmacophore activity. Indeed, in all
azobenzene derivatives of benzodiazepines (allosteric potentia-
tors of GABAAR) this characteristic property is abolished, as
found in the 7-amino site of nitrazepam, which is reportedly
tolerant of other substitutions.[15] In addition, GABAAR photo-
switches described so far are agonists or antagonists that inter-
fere with endogenous neurotransmission, not pure modula-
tors.[13, 16, 17]
Here we introduce Fulgazepam (compound 4), a derivative
of diazepam based on a different photochromic group (fulgi-
mide), which shows both quantitative reversible switching and
GABAAR potentiation. It is inactive in its open isomer and po-
tentiates the receptor in its closed isomer without concomitant
agonist or antagonist activity, thus overcoming the above
mentioned hurdles and displaying an ideal photopharmacolog-
ical profile. Most importantly, Fulgazepam works both in vitro
and in vivo, which indicates that the compound is devoid of
toxicity and has favourable molecular properties enabling wide
applications.
In contrast to azobenzenes, dithienylethenes, fulgides and
their fulgimide-named amide derivatives generally feature high
photostationary states (PSS) with both photoisomers being
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thermally stable.[7, 18] As dithienylethenes often lack of switch-
ing efficiency and stability in polar solvents due to a twisted
intramolecular electron charge transfer,[20–22] we chose
fulgi(mi)des as photochromic scaffold in this study. Both sub-
types can be interconverted between their flexible, less-col-
oured ring-open and their rigid, more coloured ring-closed
isomer upon light-induced conrotatory 6p-electrocyclic rear-
rangement (Figure 1, Scheme 1).[18, 23] Although switching from
the open to the closed form is usually triggered using UV light,
this might be avoided by the isolation and separate applica-
tion of both isomers. In addition, this ensures the application
of quantitative amounts of either the open or the closed form.
Thereby, a biological effect can clearly be assigned to one or
the other conformation. Synthetic investigations revealed the
beneficial effects of an isopropyl group in the alpha bridge po-
sition of the fulgide, as the E–Z isomerization of the open
isomer is suppressed due to steric hindrance and consequently
only two distinct isomers are observed (Figure 1 A).[19]
One advantage of fulgimides over fulgides is their improved
switching in aqueous solutions and high stability. Furthermore,
the two-step transformation of fulgides towards fulgimides via
nucleophilic ring-opening of the anhydride by a primary amine
and subsequent recyclization allows the smooth introduction
of amino-functionalized biomolecules.[18, 19] However, few bio-
logical applications of fulgi(mi)des are reported.[24–26] The trans-
formation of a known ligand into a photoresponsive molecule
can be designed by either extending the pharmacophore with
a photoswitch or via incorporation of the photochromic scaf-
fold as part of the drug’s chemical structure. Once introduced,
ideally one isomeric state is biologically active whereas the
other loses its required interactions. In the presented work,
both approaches were pursued. On the one hand, a furan-ful-
gide photochromic scaffold was merged with an amino-benzo-
diazepine under fulgimide formation (Figure 1 B, left panel). A
difference in activity can be expected from the different flexi-
bility of the isomeric states. On the other hand, a functional-
ized diazepine was synthesized aiming for a photochromic
benzodiazepine core (Figure 1 B, right panel). In this case, the
difference in activity was expected to be given by the different
conjugation of the pharmacophore’s aromatic system upon
switching. Unfortunately, the latter modified pharmacophore
(compound 9, Figure 2 B) was inactive in patch-clamp studies
(data not shown) and the synthesis towards the photoswitch
was not further pursued.
To obtain a photochromic pharmacophore core, we envi-
sioned a functionalized diazepine derivative (7) providing an
acetyl group in position 3 required for Stobbe[28–30] condensa-
tion towards fulgide formation and a methyl-group in position
2 beneficial for the fulgide’s switching performance.[25] For dia-
zepine formation, the highly functionalized precursor 7 re-
quires in addition a primary amine in position 5 and a phe-
none substitution in position 4.[27] Based on the literature
known Gewald-reaction[31] and screening of solvents and bases
the desired functionalized furan 7 was obtained in good yield
in a one-step synthesis starting from commercially available
benzoylacetonitrile 5 and 3-chloroacetylaceton 6 (Fig-
ure 2 B).[32, 33] The following ring closure required for diazepine
formation of 9 was performed in analogy to literature re-
ports.[27]
Regarding the photochromic properties, the introduction of
the bulky isopropyl group on the 1,3,5-hexatriene system of
the fulgide avoided the undesired UV light induced E–Z iso-
merization of the open E-fulgimide isomer (Figure 1 A). Only
the E isomer undergoes a photocyclization reaction to the
thermally stable closed isomer (Figure 3 A). The colorless open
isomers 3 a and 4 a were converted to their strongly colored
ring closed isomers 3 b and 4 b upon illumination with UV
light of l= 365 nm. The absorption maximum of the open
Figure 1. A) Furan-fulgimide in its open and closed isomeric state intercon-
vertible by illumination with UV and visible light.[18, 19] B) Left: Pharmaco-
phore nitrazepam and its extension towards a photochromic fulgimide.
Right: Derivatization towards a photochromic diazepine fulgide hybrid.
Figure 2. A) Synthesis of fulgimide-nitrazepam 3 a and its iso-fulgimide de-
rivative 4 a. We performed the reaction of furano-fulgide 2[25] with amino-ni-
trazepam 1[27] upon addition of dicyclohexylcarbodiimide (DCC), diisopropy-
lethylamine (DIPEA), and 1-hydroxybenzotirazole (HOBt) in methanol, to
afford the desired benzodiazepine-furano-fulgimide 3 a and its iso-fulgimide
derivative 4 a. B) Synthesis of the highly functionalized furan 7 and its diaze-
pine formation towards compound 9.[21, 24–26]




isomer around 340 nm decreased and a new maximum around
520 nm representing the closed isomer formed (Figure 3 B).
Both compounds show almost quantitative ring-closing (93 %
for 3 b and 95 % for 4 b, measured 50 mm in DMSO) and quanti-
tative ring-reopening using green light (l= 505 nm or
528 nm).
To characterize Fulgazepam in vitro, patch clamp experi-
ments were performed on cells transiently expressing a1b2g2
subunits of the GABAA receptor. This receptor possesses the
canonical benzodiazepine allosteric site and its EC50 for GABA
is about 8 mm.[14] The effects of the fulgimide-based benzodia-
zepine derivatives 3 and 4 on the receptor’s function were
studied upon co-application of 0.5 mm GABA, that is, a concen-
tration below the EC50 (close to EC3) that allows to observe al-
losteric potentiation of GABAAR-mediated currents.
[34]
Application of compound 4 a (open isomer) (10 mm) caused
no significant effect on GABAA-mediated currents, while appli-
cation of 4 b (closed isomer), generated by pre-illumination
with UV light (365 nm), induced an increase of GABAA-mediat-
ed current amplitudes (Figure 4 A). Thus, the isomers of com-
pound 4 interact differently with GABAARs, being inactive in
the open form and potentiating in the closed form. Analysis of
a series of dose-response curves established that the EC50 for
4 b was 13 mm (n = 6; Figure 4 B). Figure 4 C demonstrates that
UV illumination switches the conformation of 10 mm com-
pound 4 (from 4 a to 4 b) and increases the amplitude of
GABA-induced currents by 228:41 % (Figure 4 D; n = 11). Com-
pound 3 a in its open state co-applied with GABA (0.5 mm) in-
duced a strong potentiation of GABAAR-mediated currents (Fig-
ure S3A). This potentiation was not sensitive to illumination by
UV light and subsequent isomerization to the closed isomer
3 b (Figure S3 B) and the kinetics of compound 3 b’s develop-
ment (slow wash-in and slow wash-out) was similar to the one
of 4 b. Application of 10 mm of 3 a increased the current ampli-
tude by 292:65 %, while 50 mm of 3 a increased the current
amplitude by 544:107 % (n = 11). The EC50 of 3 a was 12 mm,
similar to the one of compound 4 b (Figure S3 C, n = 11). The
degree of GABAAR potentiation induced by 3 a markedly varied
for different cells (cf. A and B in Figure S3). A similar behavior
was observed for 4 b. We suggest that this effect reflects the
variability in the EC50 of GABA in different cells, as it has been
shown that allosteric potentiation decreases at high GABA con-
centrations.[35]
The outstanding photopharmacological profile of Fulgaze-
pam (4) as GABAAR potentiator prompted further assays in
vivo. Studies in zebrafish larvae show that the compound
alters their behavior depending on isomerization and that this
effect can be maintained over time in the absence of illumina-
tion. As both compound states 4 a and 4 b are stable in the
dark, larvae behaviors could be studied using pre-illuminated
Figure 3. A) Illumination induced ring-closing (4 b) and ring-opening (4 a) of iso-fulgimide 4 (Fulgazepam). B) Photochromic properties of iso-fulgimide 4
(50 mm) measured in DMSO. Left: Spectral evolution of 4 a (open isomer; grey spectrum) upon illumination with 365 nm and re-opening of 4 b (closed
isomer; purple spectrum) upon illumination with 528 nm. Right: Cycle performance of 4 upon alternate illumination with 365 nm (ring closing) and 528 nm
(ring opening) detected at 518 nm (lmax closed isomer). UV–Vis absorption spectrum and cycle performance of isofulgimide 4 upon illumination with 365 nm
and 505 nm. Black arrows indicate the spectral evolution upon illumination. Dotted black arrows label isosbestic points indicating a clear two component
switching. After 10 s illumination at l= 365 nm the closed-PSS was reached and 93 % of the closed-isomer accumulated. Quantitative reopening was achieved
within 120 s illumination at l= 505 nm or 528 nm, respectively. Both compounds show sufficient fatigue resistance for photopharmacological experiments
over ten measured cycles upon alternate illumination with 365 nm for closing and 528 nm for opening.




compounds in the dark followed by in situ illumination using
365 and 500 nm wavelengths (Figure 3). Pre-illuminated com-
pound 4 b altered in a dose dependent manner the behavior
of undisturbed larvae. In particular,100 mm 4 b evoked an in-
crease in swimming distance (Figure 5 B, top). The effect of
subsequent illumination was also studied. For all concentra-
tions of 4 a, UV light (hence, photoconversion to 4 b) signifi-
cantly increased larvae motility, and this effect was potentiated
during the following dark period and reduced to vehicle levels
upon illumination with visible light (Figure 5 A and Figure 5 B,
bottom). Therefore, these changes in larvae motility are trig-
gered by conformational changes of compound 4 rather than
by natural photoresponsive behaviors. A significant increase in
larvae activity, above vehicle levels, is observed when 4 b iso-
merisation is potentiated (during and after UV illumination)
and lowers to natural activity when 4 a is recovered with green
illumination independently of the initial Fulgazepam state that
is administered to larvae.
In summary, we have achieved the functionalization of the
benzodiazepine nitrazepam via extension by a fulgimide and
report a new photochromic potentiator of GABAARs. The syn-
thesized fulgimides 3 and 4 (Fulgazepam) display good photo-
chromic properties and high photostationary states. Both fulgi-
mides preserve the GABAAR potentiator behavior that is char-
acteristic of benzodiazepines, indicating that it is a pharmaco-
logically tolerable substitution, in contrast to azobenzenes at
the same position. Remarkably, both fulgimides are photochro-
mic but only Fulgazepam (4) enables controlling the pharma-
cological activity with light. The open conformation of Fulgaze-
pam (4 a) does not influence the amplitude of GABAAR currents
in vitro, while switching to its closed form 4 b with UV light
strongly potentiates them. The open (4 a) and closed (4 b) con-
formation of iso-fulgimide 4 produce different behavioral out-
comes in zebrafish larvae. The ring-open isomer 4 a does not
alter larvae swimming activities, neither applied directly nor
obtained by illumination cycles, and the closed conformation
4 b increases larvae motility in a dose dependent manner both
during prolonged dark periods and under UV illumination.
Hence, Fulgazepam photoswitching reversibly controls the be-
havior of larvae, producing high activity swimming upon
UV illumination, which persists for continuous dark periods,
and reducing activity to control levels with visible light illumi-
nation.
GABAARs mediate fast inhibition of neural activity and are
determinant in cognition, learning, and memory.[36–38] Malfunc-
tion of these receptors leads to epilepsy, anxiety, depression
and sleep disorders.[37] Clinical treatments with GABAAR modu-
lators have limited efficacy and adverse side effects,[39, 40] which
Figure 4. The effect of compounds 4 a and 4 b on GABAA-mediated currents. A) Upper panel : representative traces of currents induced by application of
GABA 0.5 mM and by mixture of GABA 0.5 mM with 4 a 10 mM; lower panel : representative traces of currents induced by application of GABA 0.5 mM and by
mixture of GABA 0.5 mM with 4 b 10 mM. Durations of applications of GABA and compound 4 are indicated by black bars above the traces. B) Cumulative
dose-response curve for compound 4 b (n = 6). C) Representative traces demonstrating the effect of 4 a photoswitching on the amplitude of GABA-induced
currents. On the left: current was induced by application of GABA 0.5 mM; on the right: at the same trace current was induced subsequently by GABA 0.5 mM,
by mixture of GABA with 4 a 10 mM under visible light and upon illumination with UV light (4 b). Duration of UV illumination is indicated by a violet rectangle.
Note the prominent increase of the GABA-induced current in the presence of 4 during illumination with UV light, which triggers ring-closing (4 b). D) Cumula-
tive graph representing mean relative amplitude of currents induced by application of GABA 0.5 mM (black column), GABA 0.5 mM + 4 a 10 mM (green column)
and GABA 0.5 mM + 4 b 10 mM (violet column) upon illumination with UV light (n = 11).




could be alleviated by targeting drug action at specific circuits
or locations.
We have recently developed an azobenzene-nitrazepam
based compound (Azo-NZ1) that allows photo-modulation of
GABAA receptors.
[14] In trans-configuration, this compound se-
lectively interacts with the chloride-permeable channel causing
inhibition of GABA-induced currents, while UV-induced transi-
tion to the cis-state results in channel unblocking and restoring
the current amplitude. Such unexpected action for a derivative
of benzodiazepine (a GABAAR potentiator) was explained by
molecular docking calculations and mutagenesis analysis indi-
cating that the 2’ residue of the channel-forming transmem-
brane TM2 domain is the target of Azo-NZ1 blocking action.
In contrast to Azo-NZ1, the GABAAR modulator presented
here (Fulgazepam) does produce potentiation of GABA-in-
duced currents. This GABAAR photoswitch displays unique
characteristics as a direct result of its photochromic (fulgimide)
and pharmacological (diazepam) moieties: (i) the fulgimide
scaffold imparts complete reversible switching of Fulgazepam’s
conformation; (ii) both Fulgazepam states are stable and can
be readily obtained by illumination with light of the appropri-
ate wavelengths; (iii) Fulgazepam is sufficiently soluble in aque-
ous solution and effectively photocontrols endogenous GA-
BAARs in vitro–in its closed form it is a pure potentiator of GA-
BAARs without agonist or antagonist activity; (iv) Fulgazepam
does not display toxicity in zebrafish and allows controlling
their behavior with light. These outstanding molecular proper-
ties enable dissecting the mechanisms of GABAergic neuro-
transmission at high spatiotemporal resolution, and pursuing
novel phototherapies based on localized, acute, and reversible
neuroinhibition.
Experimental Section
All animal experiments were conducted according to the EU Direc-
tive 2010/63/EU on the protection of animals used for scientific
purposes. According to this directive, zebrafish are considered ver-
tebrates and therefore subject to legislation governing animal test-
ing, but embryos and non-independently feeding form larvae are
excepted.
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